PA-BOOMI
22.2.2024 17:18:30 CET | Business Wire | Press release
BoomiTM, the intelligent integration and automation leader, today announced that Gartner has positioned Boomi as a Leader and placed the company highest for Ability to Execute in its Magic Quadrant for Integration Platform as a Service (iPaaS). This will be the tenth consecutive time Boomi has been named a Leader in the Gartner Magic Quadrant for iPaaS. Gartner evaluated 17 iPaaS providers on their Ability to Execute and Completeness of Vision.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240221163767/en/
Boomi Celebrates Being Positioned Highest for Ability to Execute in the Gartner® Magic Quadrant™ for Integration Platform as a Service (Graphic: Business Wire)
“We believe that being positioned highest for Ability to Execute and recognized as a 10x Leader in the Gartner Magic Quadrant for iPaaS underscores our unrelenting product excellence, innovation, and execution as a team,” said Steve Lucas, CEO at Boomi. “We are pushing the envelope further than ever before to bring groundbreaking innovations to market for the benefit of our customers and partners worldwide, and it is gratifying to see the industry take note of our considerable achievements.”
Trusted by more than 20,000 customers across all industries globally for its speed, ease-of-use, and lower total cost of ownership, the cloud-native, unified, low code, scalable, open, secure, and intelligent Boomi platform helps organizations quickly and easily accelerate business outcomes.
Boomi recently announced significant updates to its platform and business, including:
Product Innovation
- Event Streams – Available through Boomi and in AWS Marketplace, the multi-tenant enterprise message queuing and streaming service allows organizations to create integrations that are more resilient, scalable, and real-time than traditional point-to-point integration processes.
- Boomi AI – Leveraging deidentified metadata, patterns, and best practices from 200 million integrations made with the Boomi platform, Boomi AI offers a simplified user experience that harnesses generative AI to connect and integrate applications, data, processes, people, and things across organizations.
- Boomi GPT – The first offering available in the Boomi AI suite, Boomi GPT brings a simple, conversational experience to the Boomi platform. With Boomi GPT, organizations can harness the power of generative AI to integrate and automate faster than ever before, further democratizing innovation and accelerating business outcomes.
- AI Patents – This year Boomi achieved two new technology patents in the field of AI that challenge the existing paradigms inherent when constructing integration processes. These patents provide additional testament to the company’s innovation leadership and dedication of its talented team of engineers, scientists, and innovators.
- New ISO Certifications – Boomi’s ISO 27001 and 27701 certifications demonstrate the company’s continued commitment to information security and privacy compliance. As one of the only iPaaS vendors that is also FedRAMP Authorized, Boomi is consistently evolving to ensure its compliance security and privacy programs continue to meet the stringent regulatory standards set by governments and its more than 20,000 worldwide customers.
- StateRAMP Authorization – Achieving StateRAMP Authorization reflects Boomi’s unwavering commitment to data security and compliance, and to delivering a secure and reliable solution that government agencies can rely on to safeguard their data and operations.
Business Growth
- Global Growth – Boomi continues to expand globally with recently opened offices in Vancouver, Barcelona, Bengaluru, and a new headquarters based in Conshohocken, PA.
- Leadership Expansion – To help usher Boomi into its next stage of growth, the company welcomed several new executive leaders throughout the past year with experience from Adobe, Business Objects, CA Technologies, Citrix, Marketo, Salesforce, and SAP.
As a category-leading, global software as a service (SaaS) company, Boomi touts a growing community of more than 100,000 members, and one of the largest arrays of global systems integrators (GSIs) in the iPaaS space. The company boasts a worldwide network of approximately 800 partners, and works with the largest hyperscaler cloud service providers.
Boomi has won numerous awards for product innovation and being an employer of choice, including being named to the 2024 list of Best Places to Work by Built In and the CRN Cloud 100 list for innovation in cloud-based technology development. In addition, Boomi has received the prestigious 5-star rating in the CRN Partner Program Guide for two consecutive years, was named a Fire Award honoree for innovation by the Philadelphia Business Journal and a Gold Stevie® Award winner in the American Business Awards for Company of the Year in 2023. Boomi has also been recognized by The Software Report as a Top 100 Software Company and for having one of the Top 50 SaaS CEOs.
To learn more, read the Gartner report: “Magic Quadrant for Integration Platform as a Service.”
Additional Resources
- Learn more about what Boomi’s placement in the Gartner Magic Quadrant for iPaaS means
- Follow Boomi on X (Twitter), LinkedIn, Facebook, and YouTube
Gartner Disclaimer:
Gartner, Magic Quadrant for Integration Platform as a Service, Keith Guttridge, Andrew Comes, Shrey Pasricha, Max van den Berk, Andrew Humphreys, February 19, 2024
Boomi was recognized as Dell Boomi in 2014-2019. The report was previously titled as Magic Quadrant for Enterprise Integration Platform as a Service from 2017-2021 and in 2014. The report was titled as Magic Quadrant for Enterprise Integration Platform as a Service, Worldwide in 2015 & 2016 and as Magic Quadrant for Integration Platform as a Service, Worldwide in 2023.
Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. GARTNER is a registered trademark and service mark of Gartner and Magic Quadrant is a registered trademark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved. Note: Boomi was recognized as Dell Boomi from 2014 to 2019.
About Boomi
Boomi powers the future of business with intelligent integration and automation. As a category-leading, global software as a service (SaaS) company, Boomi celebrates more than 20,000 global customers and a worldwide network of 800 partners. Organizations turn to Boomi’s award-winning platform to connect their applications, data, and people to accelerate digital transformation. For more information, visit boomi.com.
© 2024 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240221163767/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
